NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti Tumor Activity And Improved Pharmacokinetic Profile In Preclinical Studies Presented At ECCO

Nektar Therapeutics (Nasdaq: NKTR) announced positive new preclinical data regarding its proprietary product candidate, NKTR-102 (PEG-irinotecan), which is under development for the treatment of solid tumors. NKTR-102 is a PEGylated form of irinotecan created using Nektar’s innovative small molecule PEGylation technology platform. The data were presented at the 14th Annual European Cancer Conference (ECCO 14). [click link for full article]

More: continued here

Comments are closed.



Get Rx Pharmacy - : Get Rx Pharmacy
Online RX Pharmacy - Buy Drugs: Online Rx pharmacy
Pay Less for Generic - : Pay Less for Generic
Pills Value - : Pills Value
RX Pharmacy Online - Buy Drugs: RX Pharmacy online
RX Discount Plus - Buy Drugs: Discount plus - A method that you get extra money even if you take discount products.
Your Health Rx - : Your Health Rx
Prescript aware - : Prescript aware
Latest News...